Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma

Yoshikazu Harada1,2 · Hiroto Izumi3 · Hirotsugu Noguchi1 · Akihiro Kuma4 · Yuichiro Kawatsu5 · Tomoko Kimura5 · Shohei Kitada1,6 · Hidetaka Uramoto7 · Ke-Yong Wang1,8 · Yasuyuki Sasaguri1,9 · Hiroshi Hijioka10 · Akihiko Miyawaki2 · Ryoichi Oya2 · Toshiyuki Nakayama1 · Kimitoshi Kohno11 · Sohsuke Yamada1,12,13

Accepted: 12 August 2015 / Published online: 22 August 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract The polypeptide N-acetylgalactosaminyltransferase (GalNAc-Ts) family of enzymes regulates the critical initial steps of mucin-type O-glycosylation. Among GalNAc-Ts that may significantly influence cancer biology, thus affecting cell differentiation, adhesion, invasion, and/or metastasis, GalNAc-T3 exhibits a high expression in several human cancers, closely associated with tumor progression and a poor prognosis. However, the expression pattern of GalNAc-T3 in oral squamous cell carcinoma (OSCC) remains obscure. Since postoperative recurrence of even early stage OSCC (ESOSCC) occurs at an early phase, significantly affecting their clinical course and worse outcome, the identification of clinically significant accurate biomarkers is needed. Therefore, we investigated the correlation between the immunohistochemical GalNAc-T3 expression and various clinicopathological characteristics and recurrence using 110 paraffin-embedded tumor samples obtained from patients with surgically resected ESOSCC (T1–2N0). Recurrence was

Yoshikazu Harada and Sohsuke Yamada contributed equally to this work.

Electronic supplementary material The online version of this article (doi:10.1007/s13277-015-3928-7) contains supplementary material, which is available to authorized users.

Sohsuke Yamada sousuke@med.ueoh-u.ac.jp

1 Department of Pathology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan
2 Department of Dentistry and Oral Surgery, University Hospital of Occupational and Environmental Health, Kitakyushu 807-8555, Japan
3 Department of Occupational Pneumology, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan
4 Department of Second Internal Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan
5 Department of Health Policy and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan
6 Department of Urology, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan
7 Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan
8 Shared-Use Research Center, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan
9 Laboratory of Pathology, Fukuoka Wajiro Hospital, Fukuoka 811-0213, Japan
10 Department of Oral and Maxillofacial Surgery, Field of Oral and Maxillofacial Rehabilitation, Advanced Therapeutics Course, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima 890-8520, Japan
11 Asahi-Matsumoto Hospital, Kitakyushu 800-0242, Japan
12 Institute of Pathology, Medical University of Graz, Graz 8010, Austria
13 Institute of Molecular Biosciences, University of Graz, Graz 8010, Austria
recognized in 37 of 110 (33.6 %) patients. The GalNAc-T3 expression was considered to be strongly positive when 20 % or more of the cancer cells showed positive cytoplasmic staining. Consequently, a strong expression of GalNAc-T3 was observed in 40 patients (36.4 %), showing a close relationship to poor differentiation, the presence of lymphatic and vascular invasion, and recurrence. Univariate and multivariate analyses further demonstrated that the patients with a strong GalNAc-T3+ status had markedly lower disease-free survival (DFS) rates, especially within the first 2 years postoperatively. Therefore, GalNAc-T3 might play a role in the pathogenesis of ESOSCC recurrence, and its immunohistochemical detection potentially predicts a shorter DFS and may be a useful parameter for providing clinical management against ESOSCC in the early postoperative phase.

**Keywords** Oral squamous cell carcinoma (OSCC) · Polypeptide N-acetylgalactosaminyltransferase 3 (GalNAc-T3) · Early stage OSCC (ESOSCC) · Vessel invasion · Disease-free survival (DFS)

**Introduction**

Oral cancer is the most common head and neck cancer, which is the sixth most common malignancy worldwide, including in Japan. Currently, approximately 264,000 new cases are diagnosed each year, with oral squamous cell carcinoma (OSCC) comprising more than 90 % histological types of these cases. Of these cases, more than 128,000 patients die of the disease annually, and the mortality rate of OSCC is 3.7 per 100,000 in Japan alone [1–3]. Among various clinicopathological characteristics, local recurrence and/or regional lymph node metastasis in cases of postoperative OSCC in particular have been proposed to be prognostic indicators [4–6]. Even early stage OSCC (ESOSCC) lesions treated with surgery alone, which more than 80 % can be cured by therapy, may exhibit postoperative relapse within the first 2 to 3 years [6–8]. Therefore, it is critical to predict which ESOSCC patients (T1–2N0) are prone to recurrence/metastasis and mortality after surgery using practically accurate biomarkers. The clinical picture of OSCC is also significantly determined by the complex interplay among additional cellular alterations, e.g., epigenetic modulation of the gene expression, at least in part [1, 4].

It is well known that the malignant transformation and cancer progression have a close relationship with alterations in cell surface carbohydrate antigens (CAs), as well as frequent aberrant glycosylation [9]. Glycosylation, a major type of post-translational modification of most secretory and cellular proteins, is capable of altering their physiochemical properties and biological activities, leading to change the functions of glycoproteins and transform cellular phenotypes, especially in cancer.

O-glycosylation reportedly encompasses diverse classes of glycoproteins and, particularly, mucin-type O-linked glycans constitute up to 80 % of the total amount of CAs in mammals [9–11]. Mucin-type O-glycosylation is initiated by uridine diphosphate (UDP) N-acetyl-α-D-galactosamine polypeptide (GalNAc) N-acetylgalactosaminyltransferases (GalNAc-Ts). GalNAc-Ts can catalyze the transfer of GalNAc from the sugar donor UDP-GalNAc to serine and threonine residues on protein synthesizing CAs in the Golgi apparatus and are the largest glycosyltransferase enzyme families covering a single known glycosidic linkage [12–14]. Abnormal O-linked glycans expressed in many epithelial cancers are markedly associated with the presentation of incompletely elongated and shortened glycan structures, which may affect cell differentiation, adhesion, invasion, and/or metastasis [10, 11]. The GalNAc-Ts, classified as 27 family members and, to date, consisting 24 members in human, show a tissue-specific expression and have different kinetic properties and acceptor substrate specificities [14]. Many studies, including ours, have indicated that GalNAc-T3 should be significantly useful for evaluating various types of carcinoma, including digestive tract adenocarcinoma, lung adenocarcinoma, renal cell carcinoma, prostatic adenocarcinoma, and ovarian adenocarcinoma [11, 15–24]. In contrast, there are no studies of possible associations between the GalNAc-T3 expression in OSCC, especially ESOSCC, and associated clinicopathological features, such as patterns of tumor invasiveness, vessel permeation, or the patient’s prognosis.

In the present study, we show for the first time that, in patients with postoperative ESOSCC, a cytoplasmic strong GalNAc-T3 expression is significantly correlated with a shortened disease-free survival (DFS) and that this molecule might be a promising biomarker for the clinical management of ESOSCC.

**Materials and methods**

**Patients**

All intended procedures in the present study, including the use of specimens obtained from human subjects, were approved by the Ethics Committee of the University of Occupational and Environmental Health (UOEH) in Kitakyushu, Japan (permission number H27-004), as well as written consent of the patient’s next of kin according to the guidelines of the Japanese Society of Pathology. Pathological reports were reviewed to identify patients who had undergone surgical resection without neck lymph node dissection for ESOSCC between 1994 and 2015 at the hospital of UOEH.

There were no patients with perioperative death, defined as death during the initial hospitalization or within 30 days of surgery. A total of 110 surgically resected ESOSCC (T1–2N0)
patients with available follow-up data comprised the cohort of this retrospective study, as shown in Table 1, after further excluding those with the following characteristics: (a) other prior or concomitant malignant tumors; (b) coexisting medical problems of sufficient disease severity to shorten life expectancy; (c) involvement of the resection margin; and (d) the use of neoadjuvant chemotherapy or radiotherapy prior to surgery. The surgical margins were considered to be involved when the presence of invasive carcinoma and/or carcinoma in situ at the margin of the mucosa was identified, or the distance to the non-carcinomatous mucosa margin was less than 5 mm.

Clinical information was thoroughly gathered from the patients’ records. The duration of survival (DFS and OS) was defined as the interval from the date of surgery to recurrence and death or the most recent clinic visit, respectively. In this study, “recurrence” (37 cases; 33.6 %) included “local recurrence,” “subsequent regional lymph node metastasis,” and “locoregional recurrence.” “Local recurrence” (13 cases; 11.8 %) was defined as lesions arising in the oral cavity relative to the primary tumor beyond 6 weeks within the first 5 years after the first definitive treatment. Meanwhile, recurrence arising in the neck was defined as “subsequent regional lymph node metastasis” (29 cases; 26.4 %), and recurrence arising at both the primary site and in the neck was defined as “locoregional recurrence” (5 cases; 4.5 %), as shown in Table 2. Patients with recurrence considered to be potentially curable and operable (35 cases; 31.8 %) underwent salvage surgery with radiotherapy (eight cases) or radiotherapy and adjuvant chemotherapy (six cases), as follows: carboplatin (two cases), fluorouracil plus carboplatin (two cases), cetuximab (one case), and docetaxel (one case), respectively. Another two inoperable (1.8 %) patients received radiotherapy and chemotherapy, as follows: fluorouracil plus carboplatin (one case) and cetuximab (one case). All patients were followed up every 2 weeks and 1 month within the first and second postoperative year, respectively, and at approximately 2- to 6-month intervals thereafter using visual inspection of the oral cavity and/or neck CT scans. Chest X-ray was performed every 6 months for 5 years after surgery. Additional examinations, including brain, chest and abdominal CT, MRI, and bone scintigraphy, were performed rarely in cases involving signs or symptoms of recurrence.

**Tissue specimens**

Formalin-fixed, paraffin-embedded tissue blocks were provided by our Department of Pathology. Three pathologists examined all resected specimens to confirm the histopathological features. The stage grouping of the tumors was classified according to the TNM classification of malignant tumors, seventh edition [25]. The mode of invasion was examined at the host/tumor interface as previously defined by Yamamoto et al. [26]. Each patient was assigned an Eastern Cooperative

| Characteristic                        | Patients (n=110) |
|--------------------------------------|-----------------|
| Age (years)                          |                 |
| Average                              | 64.3            |
| Median                               | 67              |
| Range                                | 21–92           |
| >60                                  | 78              |
| ≤60                                  | 32              |
| Sex                                   |                 |
| Male                                 | 61              |
| Female                               | 49              |
| ECOG PS                              |                 |
| ≤1                                   | 100             |
| ≥2                                   | 10              |
| Follow-up months                     |                 |
| Average                              | 67.2            |
| Median                               | 56.6            |
| Range                                | 1–236           |
| Tumor location                       |                 |
| Tongue                               | 65              |
| Maxilla                              | 7               |
| Mandible                             | 9               |
| Buccal                               | 10              |
| Floor of mouth                       | 18              |
| Hard palate                          | 1               |
| Tumor size (cm)                      |                 |
| Average                              | 2               |
| Median                               | 2               |
| Range                                | 0.2–3.8         |
| T stage                              |                 |
| T1                                   | 59              |
| T2                                   | 51              |
| Tumor differentiation                |                 |
| Well                                 | 68              |
| Moderately                           | 30              |
| Poorly                               | 12              |
| Mode of invasion                     |                 |
| 1                                    | 16              |
| 2                                    | 28              |
| 3                                    | 54              |
| 4C                                   | 9               |
| 4D                                   | 3               |
| Vascular invasion                    |                 |
| v(−)                                 | 101             |
| v(+)                                 | 9               |
| Lymphatic vessel invasion            |                 |
| ly(−)                                | 92              |
| ly(+)                                | 18              |
| Perineural involvement               |                 |
| ne(−)                                | 107             |
| ne(+)                                | 3               |

ECOG PS Eastern Cooperative Oncology Group performance status, v vascular invasion, ly lymphatic vessel invasion, ne perineural involvement
Oncology Group performance status (ECOG PS) score at the time of diagnosis [27]. Non-carcinomatous tissue and recurrent OSCC tissue were obtained from non-tumor portions of the surgically resected specimens and metastatic regional lymph nodes or locally recurrent oral mucosa corresponding to each primary site, respectively. These tissues were stained with hematoxylin and eosin (H&E), Elastica van Gieson (EVG), or immunohistochemistry preparations of sequential sections. EVG, immunohistochemical Podoplanin (D2-40; Nichirei Bioscience Co., Tokyo, Japan; diluted 1:1), and S-100 protein (Dako, Glostrup, Denmark; diluted 1:900) staining very clearly revealed vascular invasion (v), lymphatic vessel invasion (ly), and perineural involvement (ne), respectively, as previously described [28].

Preparation of antibodies against GalNAc-T3 and other GalNAc-Ts

A polyclonal antibody was raised against GalNAc-T3 using multiple immunizations of New Zealand white rabbits with a synthetic peptide, based on previously published work (sequence: GYYTAAELKPVLDRPPQDS) [29]. An anti-GalNAc-T6 polyclonal antibody was generated in the same way, as described in a previously published paper (synthetic peptide sequence: GFYTPAELKPFWERPPQDP) [21]. The specificity of our original antibody was confirmed on Western blotting (Fig. 1). Furthermore, we performed immunohistochemistry with peptide competition against GalNAc-T3 [16, 29] and GalNAc-T6 [21], respectively. For immunohistochemistry of GalNAc-T3 (diluted 1:1,000), we used well-differentiated tubular colorectal adenocarcinoma cells as positive controls [11]. To analyze the staining or expression profiles of other GalNAc-Ts, anti-GalNAc-T1, anti-GalNAc-T2, and anti-GalNAc-T4 goat monoclonal antibodies (1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and the above anti-GalNAc-T6 (diluted 1:1,000) were applied, respectively.

Cell culture

HSC-2 (human OSCC cell line) was described previously [30] and maintained in Eagle’s minimal essential medium containing 10 % fetal bovine serum. COS-1 (monkey kidney cell line) was described previously [31] and maintained in Dulbecco’s modified Eagle’s medium containing 10 % fetal bovine serum. Cell lines were maintained at 37 °C in an atmosphere of 95 % air and 5 % CO2.

**GalNAc-T3 siRNA knockdown and overexpression**

Twenty-five base-pair double-stranded RNA oligonucleotides were commercially generated (Life Technologies, CA, USA): 5′-UUCUGCUCGUAAUAUAUCCUUGC-3′ and 5′-GCAAGGAUAUAACAGCAGCAGA-3′ for GalNAc-T3#85 and 5′-AAACUAUAUGACACUGGUGGG-3′ and 5′-CCACCACCAGUGUCAUAAU-3′ for GalNAc-T3#86. siRNA transfection was performed as previously described [11]. A total of 5 μL of RNAiMAX (Life technologies) was diluted in 250 μL of Opti-MEM medium (Invitrogen, Carlsbad, CA, USA) and incubated for 5 min at room temperature (RT). Next, 250 pmol of siRNA for GalNAc-T3 and RNAiMAX as control siRNA diluted in 250 μL of Opti-MEM were gently added and incubated for 20 min at RT. Oligomer-RNAiMAX complexes and aliquots of 2×10⁵ HSC-2 in 500 μL of culture medium were combined. To obtain pcDNA3-GalNAc-T3 expression plasmid, human full length GalNAc-T3 cDNA was amplified with the primer pairs 5′-CCATGGCTCACCTAAAGCGACTAG-3′ and 5′-TTAATCATTTTGGCTAAGTATCC-3′ and ligated in multi-cloning site of pcDNA3 mammalian expression plasmid (Invitrogen). Underlines indicate start or stop codons. Transfection of expression plasmid was described previously [32].

**Western blotting**

Transfected cells with siRNAs or expression plasmid were harvested after 48 h, and a Western blotting analysis was performed as previously described [11]. In total, 30 μg of protein from whole cell lysates was separated via sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride microporous membranes (Millipore, MA, USA). The blotted membranes were treated with 5 % (w/v) skim milk and incubated for 1 h at RT with the primary antibody (diluted 1:1,000). Next, the membrane was incubated for 45 min at RT with a peroxidase-conjugated secondary antibody and visualized using an ECL kit (GE...
Healthcare Bio-Science, Buckinghamshire, UK). Detection was performed with an LAS-4000 mini (Fujifilm, Tokyo, Japan).

**Immunofluorescence of HSC-2**

HSC-2 was cultured on coverslips, then incubated with anti-GalNAc-T3 (diluted 1:1,000) and anti-GalNAc-T6 (diluted 1:1,000) rabbit polyclonal antibodies or anti-GalNAc-T1, anti-GalNAc-T2, and anti-GalNAc-T4 goat monoclonal antibodies (diluted 1:100; Santa Cruz Biotechnology) for 1 h at RT, respectively. These cells were then further incubated with Hoechst 33258 (blue-stained) (0.5 mg/mL; Dojindo, Kumamoto, Japan) and visualized with goat anti-rabbit or donkey anti-goat IgG antibodies conjugated with Alexa Fluor dyes (green-stained), respectively [11]. After being washed with PBS, the specimens were observed under a Nikon ECLIPSE E600 inverted fluorescence microscope (Nikon, Tokyo, Japan).

**Immunohistochemistry of the tissue samples**

Immunohistochemical staining was performed according to the antibody-linked dextran polymer method for antibody-bridge labeling, with hematoxylin counterstaining (EnVision; DAKO). Deyparaffinized and rehydrated 4-μm sections were incubated in 10 % H₂O₂ for 5 min to block the endogenous peroxidase activity. The sections were subsequently rinsed and incubated with rabbit polyclonal anti-GalNAc-T3 (diluted 1:3,000) antibodies for 30 min, respectively. The second antibody-peroxidase-linked polymers were then applied, and the sections were incubated with a solution consisting of 20 mg of 3,3’diaminobenzidine tetrahydrochloride, 65 mg of sodium azide, and 20 mL of 30 % H₂O₂ in 100 mL of Tris–HCl (50 mM, pH 7.6). After counterstaining with Meyer’s hematoxylin, the sections were observed under a light microscope. Each section was first scanned at low power for all fields (original magnification: ×40) using tumor and non-tumor tissues, respectively, in order to determine the heterogeneity of the distribution. The number of positive cells showing cytoplasmic staining was recorded in the site of invasion. Necrotic tissues, stromal cells, and lymphoid cells were not included in the recordings.

The degree of immunoreactivity for GalNAc-T3 was assessed in each case semi-quantitatively by evaluating the proportion of positive cells relative to the total number of ESOSCC cells. Samples with positive areas comprising equal to or more than 20 % of the neoplasms were considered to be strongly positively stained. We selected and validated immunohistochemical cutoff scores for GalNAc-T3 positivity, based on the findings of a receiver operating characteristic (ROC) curve analysis [33]. Finally, all patients were divided into two groups, as follows: those with strongly positive findings, equal to or more than 20 %, and those with weakly positive (including negative) findings, less than 20 %.

All histological and immunohistochemical slides were evaluated by two independent observers using a blind protocol design (the observers were blinded to the clinicopathological data). The degree of agreement between the observers was excellent (an agreement rate of more than 95 %) for all antibodies investigated, as measured according to the interclass correlation coefficient. For the very few (much less than 1 %) instances of disagreement, a consensus score was calculated by a third board-certified pathologist in our department [11, 28, 34, 35].

**Statistical analysis**

The significance of correlations was determined based on χ² test or Fisher’s exact test, where appropriate, in order to assess the relationships between the immunohistochemical expression levels and the clinicopathological variables [11, 30]. Survival curves were plotted according to the Kaplan–Meier method and compared using the log-rank test. Hazard ratios...
and 95% confidence intervals (95% CIs) were estimated using univariate or multivariate Cox proportional hazard models. All statistical tests were two-tailed, with a P value of <0.05 considered to be statistically significant. All statistical analyses were performed with the EZR software program (Saitama Medical Center, Jichi Medical University, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, version 2.13.0) [35, 36]. More precisely, this program is a modified version of R commander (version 1.6-3) designed to add statistical functions frequently used in biostatistics.

Results

Confirmation of the specificity of the GalNAc-T3 antibody

Specificity, a GalNAc-T3 polyclonal antibody, was tested using immunohistochemistry and Western blotting, as previously described [11]. In this study, Western blotting revealed that GalNAc-T3 proteins were expressed in the HSC-2 cells (Fig. 1a), whereas GalNAc-T6 staining was weak (data not shown). We thus performed siRNA transfection of GalNAc-T3 into the wild-type HSC-2 cells, which demonstrated that the expression of about 90 kDa protein was significantly decreased in the HSC-2 cells of GalNAc-T3 siRNA (Fig. 1a). Further, about 90 kDa protein was detected in cells transfected with GalNAc-T3 expression plasmid (Fig. 1b). These Western blotting results indicate that the GalNAc-T3 antibody was specific for its protein. Immunofluorescence staining of the OSCC cell line (HSC-2) showed a specific expression of GalNAc-T3 in a cytoplasmic, perinuclear fashion but not in nuclei (Supplementary Fig. 1). In contrast, other GalNAc-Ts (-T1, -T2, -T4, and -T6) were not or very weakly expressed in the HSC-2 cells (Supplementary Fig. 1).

Patient characteristics

The cohort included 110 patients (61 males, 49 females) with clinicopathological variables representative of ESOSCC (Table 1). The average age at surgery was 64.3 years. A total of 100 (90.9%) and 10 (9.1%) patients had an ECOG status equal to or less than 1 and more than 2, respectively. The median tumor size was 2.0 cm (range=0.2–3.8 cm). At diagnosis, no patients had either lymph node or distant metastasis. The tumor grade included 68 well-differentiated lesions (61.8%), 30 moderately differentiated lesions (27.3%), and 12 poorly differentiated lesions (10.9%) of squamous cell carcinoma. Based on the (TNM) classification of malignant tumors, seventh edition, the ESOSCC patients had stage I (56/110; 50.9%) and II (54/110; 49.1%) disease, respectively. Postoperative follow-up was available for all 110 patients (average=67.2 months; range=1–236 months). The median OS was 56.6 months, with 2- and 5-year survival rates of 92.9 and 90.9%, respectively. Moreover, the median DFS was 26.5 months with 2- and 5-year survival rates of 67.5 and 61.9%, respectively. Supplementary Table 1 displays each patient’s information in detail.

GalNAc-T3 expression in the non-carcinomatous oral mucosal tissues, ESOSCC specimens, and recurrent OSCC specimens of lymph nodes or mucosa

On immunohistochemistry, GalNAc-T3 showed cytoplasmic expression patterns in the typically strongly positive cancer cases (Fig. 2), especially at the invasive front. Representative images of the immunohistochemical findings of the human ESOSCC samples associated with a shortened DFS (i.e., early recurrence) or no recurrence are shown in Supplementary Table 1 (case nos. 25 or 71), respectively (Fig. 2). In contrast, a cytoplasmic GalNAc-T3 expression was very weak, but on occasion, diversely, detectable of adjacent non-carcinomatous squamous epithelium (normal to dysplasia) in the paraffin-embedded tissues (Fig. 2). GalNAc-T3 was weakly and strongly positively expressed in 70 (63.6%) and 40 (36.4%) of the 110 ESOSCC specimens, respectively (Table 3 and Fig. 2). In particular, GalNAc-T3 was strongly or weakly expressed in 19 (54.3%) and 16 (45.7%) of 35 recurrent ESOSCC specimens of lymph nodes or corresponding oral mucosa, respectively. Moreover, the GalNAc-T3 staining patterns were borderline significantly consistent with those of the corresponding primary OSCC specimens (P=0.05), especially the recurrent pattern of subsequent regional lymph node metastasis (Table 2 and Supplementary Table 2), as described later in detail. Representative H&E and immunohistochemical GalNAc-T3 sections are shown with a strong expression of OSCC in both the primary oral mucosa and metastatic regional lymph nodes (case no. 21 in Supplementary Table 1) (Fig. 3).

Associations between the GalNAc-T3 expression and the clinicopathological variables and pattern of recurrence

In order to identify associations between the GalNAc-T3 expression (weakly vs. strongly positive) and the clinicopathological characteristics of the study cohort, the variables were categorized as shown in Table 3. Consequently, a GalNAc-T3 strongly positive expression was found to be significantly or borderline (in)significantly associated with poor differentiation (P=0.03), the presence of v (P=0.04) and Ly (P=0.03) and recurrence (P=0.01) or an older age (P=0.05) in all tumors (Table 3 and
Supplementary Fig. 2), respectively. In contrast, there were no significant differences between the patients with weakly and strongly positive GalNAc-T3 ESOSCC expression patterns in terms of gender, ECOG PS, smoking, alcohol use, tumor T stage, location, mode of invasion, and presence of ne (P >0.05) (Table 3). In particular, a strong GalNAc-T3+ expression was evident in v(+) and ly(+) (v; case no. 25, ly; case no. 2 in Supplementary Table 1) representative OSCC components, as shown on EVG and D2-40 staining, respectively (Supplementary Fig. 2).

Additionally, in order to elucidate the correlations between the GalNAc-T3 expression (weakly vs. strongly positive) and the pattern of recurrence in the study cohort, the variables were also categorized as presented in Supplementary Table 2. A strongly positive GalNAc-T3 expression was revealed to be borderline (in)significantly associated with “subsequent regional lymph node metastasis” (P =0.05), whereas there were no significant differences in the patterns of “local recurrence” and “locoregional recurrence” (P >0.05) (Supplementary Table 2).

According to a Kaplan–Meier analysis, the patients with a strong GalNAc-T3+ expression had a significantly shorter postoperative median DFS (11.8 months) than those with a weak GalNAc-T3+ expression (32.7 months), especially within the first 2 rather than 5 years postoperatively (P <0.001 (2 years) and P <0.01 (5 years), respectively, Fig. 4a). However, there were no significant differences in postoperative OS between the two groups of ESOSCC patients with a weak (median=62.5 months) and strong (median=53.7 months) GalNAc-T3+ status (P =0.302 (2 years) and P =0.915 (5 years), Fig. 4b).

A strong GalNAc-T3+ expression represents a significant independent DFS indicator for ESOSCC by a Cox proportional hazards model

A univariate analysis showed tumor differentiation (poorly), mode of invasion of 4C and 4D, the presence of v and ly, and a strong GalNAc-T3+ expression to be significant predictors of a worse survival (P =0.03, 0.001, 0.01 and <0.001 and <0.001, respectively). Furthermore, a multivariate analysis demonstrated that, after correcting for confounding variables, a strong GalNAc-T3+ expression only remained an independent poor indicator for DFS (P =0.03), whereas a more aggressive mode of invasion and the presence of ly were borderline (P =0.05 and 0.05, respectively) (Table 4).

Discussion

The current study showed for the first time that an immunohistochemically cytoplasmic strong GalNAc-T3-positive expression is a powerful and independent negative indicator of DFS and potential worse outcome in patients with postoperative ESOSCC, especially within the first 2 years after surgery. It is well known that recurrence in ESOSCC patients after curative surgery remains a significant problem and can significantly affect their clinical postoperative course and survival [6]. The biological aggressiveness of ESOSCC is reflected by the capability of carcinoma to recur, even in small OSCC lesions that are considered to have a relatively good prognosis [in

Collectively, our present data are in agreement with the findings of previous studies of several other epithelial cancers
For example, kidney epithelial cancer has recently shown a significantly upregulated GalNAc-T3 expression closely associated with more aggressive tumor characteristics and worse prognosis [11]. The present cohort study

Table 3  Detailed correlations between the GalNAc-T3 expression and the clinicopathological variables

| Variables                  | Total | GalNAc T3 expression (%) | Weak+ (n=70) | Strong+ (n=40) | P value |
|----------------------------|-------|--------------------------|--------------|----------------|---------|
| Age                        |       |                          |              |                | 0.05    |
| >60                        | 32    | 29.1                     | 25 (78.1)    | 7 (21.9)       |         |
| ≤60                        | 78    | 70.9                     | 45 (57.7)    | 33 (42.3)      |         |
| Sex                        |       |                          |              |                | 0.24    |
| Male                       | 61    | 55.5                     | 42 (68.9)    | 19 (31.1)      |         |
| Female                     | 49    | 44.5                     | 28 (57.1)    | 21 (42.9)      |         |
| ECOG PS                    |       |                          |              |                | 0.74    |
| 0–1                        | 100   | 90.9                     | 63 (63.0)    | 37 (37.0)      |         |
| 2–4                        | 10    | 9.1                      | 7 (70.0)     | 3 (30.0)       |         |
| Smoking                    |       |                          |              |                | 0.17    |
| (−)                        | 51    | 46.4                     | 36 (70.6)    | 15 (29.4)      |         |
| (+)                        | 59    | 53.6                     | 34 (57.6)    | 25 (42.4)      |         |
| Alcohol                    |       |                          |              |                | 0.43    |
| (−)                        | 49    | 44.5                     | 29 (59.2)    | 20 (40.8)      |         |
| (+)                        | 61    | 55.5                     | 41 (67.2)    | 20 (32.8)      |         |
| T stage                    |       |                          |              |                | 0.11    |
| T1                         | 59    | 53.6                     | 42 (71.2)    | 17 (28.8)      |         |
| T2                         | 51    | 46.4                     | 28 (54.9)    | 23 (45.1)      |         |
| Tumor location             |       |                          |              |                | 0.32    |
| Tongue                     | 65    | 59.1                     | 39 (60.0)    | 26 (40.0)      |         |
| Maxilla                    | 7     | 6.4                      | 5 (71.4)     | 2 (28.6)       |         |
| Mandible                   | 9     | 8.2                      | 4 (44.4)     | 5 (55.6)       |         |
| Buccal                     | 10    | 9.1                      | 6 (60.0)     | 4 (40.0)       |         |
| Floor of mouth             | 18    | 16.4                     | 15 (83.3)    | 3 (16.7)       |         |
| Hard palate                | 1     | 0.9                      | 1 (100)      | 0 (0)          |         |
| Differentiation            |       |                          |              |                | 0.03    |
| Well, moderately           | 98    | 89.1                     | 66 (67.3)    | 32 (32.7)      |         |
| Poorly                     | 12    | 10.9                     | 4 (33.3)     | 8 (66.7)       |         |
| Mode of invasion           |       |                          |              |                | 0.40    |
| 1–3                        | 95    | 86.4                     | 62 (65)      | 33 (32.7)      |         |
| 4C, 4D                     | 15    | 13.6                     | 8 (53.3)     | 7 (46.7)       |         |
| Vascular invasion          |       |                          |              |                | 0.04    |
| v(−)                       | 101   | 91.8                     | 62 (65)      | 33 (34.7)      |         |
| v(+)                       | 9     | 8.2                      | 2 (22.2)     | 7 (77.8)       |         |
| Lymphatic vessel invasion  |       |                          |              |                | 0.03    |
| ly(−)                      | 92    | 83.6                     | 63 (68.5)    | 29 (31.5)      |         |
| ly(+)                      | 18    | 16.4                     | 7 (38.9)     | 11 (61.1)      |         |
| Perineural involvement     |       |                          |              |                | 0.55    |
| ne(−)                      | 107   | 97.3                     | 67 (62.6)    | 40 (37.4)      |         |
| ne(+)                      | 3     | 2.7                      | 3 (38.9)     | 0 (0)          |         |
| Recurrence                 |       |                          |              |                | 0.01    |
| (−)                        | 73    | 66.4                     | 53 (72.6)    | 20 (27.4)      |         |
| (+)                        | 37    | 33.6                     | 17 (46)      | 20 (54.1)      |         |

ECOG PS Eastern Cooperative Oncology Group performance status, v vascular invasion, ly lymphatic vessel invasion, ne perineural involvement
demonstrated GalNAc-T3 to be a powerful and independent negative indicator of DFS, i.e., a novel marker of recurrence, in patients with postoperative ESOSCC. As to the OS, there were no apparent correlations with a strong GalNAc-T3+ expression of ESOSCC in our study, with the limitations of assessing an unlikely large cohort at a single institution. In fact, all collected patients had surgically resected T1–2N0 ESOSCCs with a more favorable prognosis, showing a 5-year survival rate of 90.9 % compared with that of up to 86 % reported in previous studies [6]. Further follow-up with a larger cohort is therefore needed to confirm the intriguing relationships between a strong GalNAc-T3+ expression and poor outcome in postoperative ESOSCC patients.

Our findings indicate for the first time that a strong GalNAc-T3+ expression in ESOSCC is significantly closely correlated with poor differentiation and the presence of vessel

Fig. 3 GalNAc-T3 staining patterns significantly corresponding to the primary ESOSCC specimens. Representative immunohistochemical GalNAc-T3 sections are presented with a strong expression of early recurrent ESOSCC in both the primary oral mucosa and metastatic regional lymph node (case no. 21). H&E hematoxylin and eosin. Bars=200 μm (×100) and 20 μm (×400)

Fig. 4 A strong GalNAc-T3-positive expression was associated with a significantly shorter postoperative DFS, but not OS, in the ESOSCC patients, especially within the first 2 years postoperatively. a Kaplan–Meier curves for DFS in the patients with ESOSCC within the first 2 (left) and 5 (right) years after surgery according to the GalNAc-T3 expression. b Kaplan–Meier curves for OS in the patients with ESOSCC within the first 2 (left) and 5 (right) years after surgery according to the GalNAc-T3 expression. DFS disease-free survival, OS overall survival
permeation (v (+) and ly (+)), most likely manifesting as significant invasive/aggressive behaviors. These results also accord with those of our recent study of clear cell renal cell carcinoma [11], that the GalNAc-T3+ expression significantly ameliorates adhesive effects together with a significantly low expression of β-catenin, seemingly leading to severe v (+). Moreover, other groups have focused on modulation of the cell adhesion function by GalNAc-T3 overexpression, which is involved in invasion/metastasis of the ovarian adenocarcinoma via abnormal glycosylation of O-glycoprotein mucin 1.

Table 4  Univariate and multivariate analyses of survival (DFS) among the 110 patients with ESOSCC according to the clinicopathological variables and the strong GalNAc-T3 expression

| Variables                        | No. of patients (%) |         |         | Univariate HR | 95% CI     | P value |         |         |         |         |
|----------------------------------|---------------------|---------|---------|---------------|------------|---------|---------|---------|---------|---------|
|                                  | Disease-free (%)    | Disease%|         |               |            |         |         |         |         |         |
| Age                              |                     |         |         |               |            |         |         |         |         |         |
| ≤60                              | 22 (68.8)           | 10 (31.3)| 1.00   |               | 1.00       |         |         |         |         |         |
| >60                              | 51 (65.4)           | 27 (34.6)| 1.26   | 0.61–2.62     | 0.53       |         |         |         |         |         |
| Sex                              |                     |         |         |               |            |         |         |         |         |         |
| Female                           | 31 (63.3)           | 18 (36.7)| 1.00   |               | 1.00       |         |         |         |         |         |
| Male                             | 42 (68.9)           | 19 (31.1)| 0.85   | 0.45–2.30     | 0.25       |         |         |         |         |         |
| ECOG PS                          |                     |         |         |               |            |         |         |         |         |         |
| 0–1                              | 64 (64.0)           | 36 (36.0)| 1.00   |               | 1.00       |         |         |         |         |         |
| 2–4                              | 9 (90.0)            | 1 (10.0)| 0.31   | 0.04–2.30     | 0.25       |         |         |         |         |         |
| Smoking                          |                     |         |         |               |            |         |         |         |         |         |
| (−)                              | 34 (66.7)           | 17 (33.3)| 1.00   |               | 1.00       |         |         |         |         |         |
| (+)                              | 39 (66.1)           | 20 (33.9)| 1.08   | 0.56–2.06     | 0.82       |         |         |         |         |         |
| Alcohol                          |                     |         |         |               |            |         |         |         |         |         |
| (−)                              | 22 (68.8)           | 10 (31.3)| 1.00   |               | 1.00       |         |         |         |         |         |
| (+)                              | 51 (65.4)           | 27 (34.6)| 1.55   | 0.79–3.00     | 0.20       |         |         |         |         |         |
| T stage                          |                     |         |         |               |            |         |         |         |         |         |
| T1                               | 42 (71.2)           | 17 (28.8)| 1.00   |               | 1.00       |         |         |         |         |         |
| T2                               | 31 (60.8)           | 20 (39.2)| 1.53   | 0.80–2.91     | 0.20       |         |         |         |         |         |
| Tumor location                   |                     |         |         |               |            |         |         |         |         |         |
| Maxilla, mandible, buccal        | 23 (65.7)           | 12 (34.3)| 1.00   |               | 1.00       |         |         |         |         |         |
| Tongue, floor of mouth           | 50 (66.7)           | 25 (33.3)| 1.20   | 0.50–2.40     | 0.82       |         |         |         |         |         |
| Differentiation                  |                     |         |         |               |            |         |         |         |         |         |
| Well, moderately                 | 68 (69.4)           | 30 (30.6)| 1.00   |               | 1.00       |         |         |         |         |         |
| Poorly                           | 5 (41.7)            | 7 (58.3)| 2.53   | 1.11–5.79     | 0.03       | 0.69    | 0.19–2.54 | 0.58       |         |         |
| Mode of invasion                 |                     |         |         |               |            |         |         |         |         |         |
| 1, 2, 3                          | 68 (71.6)           | 27 (28.4)| 1.00   |               | 1.00       |         |         |         |         |         |
| 4C, D                            | 5 (33.3)            | 10 (66.7)| 3.29   | 1.59–6.82     | 0.001      | 3.23    | 1.02–10.6| 0.05       |         |         |
| Vascular invasion                |                     |         |         |               |            |         |         |         |         |         |
| v (−)                            | 70 (69.3)           | 31 (30.7)| 1.00   |               | 1.00       |         |         |         |         |         |
| v (+)                            | 3 (33.3)            | 6 (66.7)| 3.54   | 1.47–8.52     | 0.01       | 2.25    | 0.87–5.78| 0.09       |         |         |
| Lymphatic vessel invasion        |                     |         |         |               |            |         |         |         |         |         |
| ly (−)                           | 68 (73.9)           | 24 (26.1)| 1.00   |               | 1.00       |         |         |         |         |         |
| ly (+)                           | 5 (27.8)            | 13 (72.2)| 3.96   | 1.98–7.91     | <0.001     | 2.18    | 1.01–4.71| 0.05       |         |         |
| Perineural involvement           |                     |         |         |               |            |         |         |         |         |         |
| ne (−)                           | 71 (66.4)           | 36 (33.6)| 1.00   |               | 1.00       |         |         |         |         |         |
| ne (+)                           | 2 (66.7)            | 1 (33.3)| 0.87   | 0.12–6.34     | 0.89       |         |         |         |         |         |
| GalNAc-T3 expression             |                     |         |         |               |            |         |         |         |         |         |
| Weak +                           | 53 (75.7)           | 17 (24.3)| 1.00   |               | 1.00       |         |         |         |         |         |
| Strong +                         | 20 (50.0)           | 20 (50.0)| 2.81   | 1.47–5.37     | 0.002      | 2.23    | 1.06–4.80| 0.03       |         |         |

v vascular invasion, ly lymphatic vessel invasion, ne perineural involvement
(MUC1), potentially accompanied by the downregulated expression of E-cadherin and β-catenin [24]. Taken together, we can support our hypotheses that GalNAc-T3 accelerates ESOSCC invasion/metastasis by affecting epithelial-mesenchymal transition (EMT) at least in part, as previously described [11, 21]. Furthermore, our immunohistochemical examination of ESOSCC tissues showed a strong subcellular cytoplasmic staining pattern for GalNAc-T3 especially at the invasive fronts. Whereas, weakly but, on occasion, diversely positive staining was identified in the adjacent non-carcinomatous squamous epithelium (normal to dysplasia). It is conceivable that GalNAc-T3 potentially plays a critical role in acquired OSCC aggressiveness as well as carcinogenesis through aberrant O-linked glycosylation. Since GalNAc-Ts reportedly appear in external secretions into body fluids [37, 38], GalNAc-T3 would be a quantitative soluble marker. In this scenario, these findings lead us to speculate that GalNAc-T3 might be not only a predictive factor of occult metastasis or specific tumor marker for OSCC but also an ideal therapeutic target against ESOSCC, together with minimum risk of side effects. Nevertheless, further in-depth in vitro and in vivo analyses, including real-time quantitative polymerase chain reaction (qRT-PCR), are needed to elucidate these issues.

In conclusion, the present cohort study demonstrated for the first time that a strong GalNAc-T3+ expression is an independent, novel, and powerful marker of a worse DFS in ESOSCC patients, especially within the first 2 years, even after curative surgery. Patients with ESOSCC showing strong GalNAc-T3+ expression should be followed up very carefully. Therefore, physicians should assess the value of this critical ESOSCC-specific biomarker, GalNAc-T3, as a useful parameter for clinical management, particularly in the early postoperative phase.

References

1. Sasahira T, Kirita T, Kuniyasu H. Update of molecular pathobiology in oral cancer: a review. Int J Clin Oncol. 2014;19(3):431–6.
2. Jermal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
3. Tong XJ, Shan ZF, Tang ZG, et al. The impact of clinical prognostic factors on the survival of patients with oral squamous cell carcinoma. J Oral Maxillofac Surg. 2014;72(12):2497–e1–10.
4. Scully C, Bagán J. Oral squamous cell carcinoma overview. Oral Oncol. 2009;45(4–5):301–8.
5. González-Garcia R, Naval-Gías L, Román-Romero L, et al. Local recurrences and second primary tumors from squamous cell carcinoma of the oral cavity: a retrospective analytic study of 500 patients. Head Neck. 2009;31(9):1168–80.
6. Yanamoto S, Yamada S, Takahashi H, et al. Predictors of locoregional recurrence in T1–2N0 tongue cancer patients. Pathol Oncol Res. 2013;19(4):795–803.
7. Capote A, Escorial V, Muñoz-Guerra MF, et al. Elective neck dissection in early-stage oral squamous cell carcinoma—does it influence recurrence and survival? Head Neck. 2007;29(1):3–11.
8. Huang TY, Hsu LP, Wen YH, et al. Predictors of locoregional recurrence in early stage oral cavity cancer with free surgical margins. Oral Oncol. 2010;46(1):49–55.
9. Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta. 1999;1473(1):67–95.
10. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4(1):45–60.
11. Kitada S, Yamada S, Kuma A, et al. Polypeptide N-acetylglactosaminyltransferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. Br J Cancer. 2013;109(2):472–81.
12. Schwientek T, Bennett EP, Flores C, et al. Functional conservation of subfamilies of putative UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferases in Drosophila, Caenorhabditis elegans and mammals. J Biol Chem. 2002;277(25):22623–38.
13. Ten Hagen KG, Fritz TA, Tabak LA. All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology. 2003;13(1):1R–16R.
14. Bennett EP, Mandel U, Clausen H. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 2012;22(6):736–56.
15. Shibao K, Izumi H, Nakayama Y, et al. Expressions of UDP-N-Acetyl-α-D-galactosaminyltransferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma. Cancer. 2002;94(7):1939–46.
16. Dosaka-Akita H, Kinoshita I, Yamazaki K, et al. N-acetylgalactosaminyltransferase-3 is a potential new marker for non-small cell lung cancers. Br J Cancer. 2002;87(7):751–5.
17. Gu C, Oyama T, Osaki T, et al. Low expression of polypeptide GalNAc N-acetylgalactosaminyltransferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence. Br J Cancer. 2004;90(2):436–42.
18. Ishikawa M, Kitayama J, Nariko H, et al. The expression pattern of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-3 in early gastric carcinoma. J Surg Oncol. 2004;86(1):28–33.
19. Miyahara N, Shoda J, Kawamoto T, et al. Expression of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase isozyme 3 in the suberosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder. Clin Cancer Res. 2004;10(6):2090–9.
20. Yamamoto S, Nakamori S, Tsujie M, et al. Expression of uridine diphosphate N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase 3 in adenocarcinoma of the pancreas. Pathobiology. 2004;71(1):12–8.

21. Li Z, Yamada S, Inenaga S, et al. Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. Br J Cancer. 2011;104(12):1882–9.

22. Landers KA, Burger MJ, Tebay MA, et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer. 2005;114(6):950–6.

23. Inoue T, Eguchi T, Oda Y, et al. Expression of GalNAc-T3 and its relationships with clinicopathological factors in 61 extrahepatic bile duct carcinomas analyzed using stepwise sections—special reference to its association with lymph node metastases. Mod Pathol. 2007;20(2):267–76.

24. Wang ZQ, Bachvarova M, Morin C, et al. Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget. 2014;5(2):544–60.

25. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours, 7th edition. Wiley-Blackwell 2009

26. Yamamoto E, Kohama G, Sunakawa H, et al. Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity. Cancer. 1983;51(12):2175–80.

27. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.

28. Kimura T, Kitada S, Uramoto H, et al. The combination of strong immunohistochemical mtTFA expression and a high survivin index predicts a shorter disease-specific survival in pancreatic ductal adenocarcinoma. Histol Histopathol. 2015;30(2):193–204.

29. Nomoto M, Izumi H, Ise T, et al. Structural basis for the regulation of UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyl transferase-3 gene expression in adenocarcinoma cells. Cancer Res. 1999;59(24):6214–22.

30. Ishida T, Hijoka H, Kume K, et al. Notch signaling induces EMT in OSCC cell lines in a hypoxic environment. Oncol Lett. 2013;6(5):1201–6.

31. Uramoto H, Izumi H, Ise T, Tada M, et al. p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem. 2002;277(35):31694–702.

32. Izumi H, Yasuniwa Y, Akiyama M, et al. Forced expression of ZNF143 restrains cancer cell. Cancers. 2011;3(4):3909–20.

33. Hanley JA. Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging. 1989;29(3):307–35.

34. Kawatsu Y, Kitada S, Uramoto H, et al. The combination of strong expression of ZNF143 and high MIB-1 labelling index independently predicts shorter disease-specific survival in lung adenocarcinoma. Br J Cancer. 2014;110(10):2583–92.

35. Takeda T, Izumi H, Kitada S, et al. The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened survival in patients with pancreatic ductal adenocarcinoma. Tumour Biol. 2014;35(10):10555–69.

36. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.

37. Hagen FK, Van Wuyckhuyse B, Tabak LA. Purification, cloning, and expression of a bovine UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase. J Biol Chem. 1993;268(25):18960–5.

38. O’Connell BC, Hagen FK, Tabak LA. The influence of flanking sequence on the O-glycosylation of threonine in vitro. J Biol Chem. 1992;267(35):25010–8.